Core A Administrative Core The Administrative Core is under the Direction of the Program Director, Dr. Richard J. Whitiey. As the responsible Principal Investigator for the Program Project Grant, he will provide the scientiflc and administrative leadership for the overall program. He will be assisted in these tasks by Drs. G. Yancey Gillespie and James M. Markert, Program Co-Directors. Together, these Administrative Core Leaders will provide centralized management support, and collaborative research support for all research projects of this two-institution Program Project Grant. The purpose of this Core is to provide the administrative framework to facilitate the rapid and expeditious translation of our basic science advances into therapeutic opportunities for humans. The interdigitation of molecular virology, cellular biology. In vitro screening, animal model studies, and other facilitating work will be coordinated by the Administrative Core. Administrative funcflons also include oversight of operations and budgetary issues for all Program Project investigators and Core Leaders. Quarterly meetings with all of the Project and Core leaders will be organized and coordinated to ensure that the research activities proceed in a timely fashion and that all program participants have an informal forum to shape and focus the direction of the research activities. These meetings will also enhance the integration of project and core activities with each other, based on priorities that are identifled from results presented at each meeting. The Administrative Core will coordinate an annual meeting with the External Advisory Committee which will evaluate the progress of the individual Program projects and the services provided by the Cores. The External Advisory Committee is compised of 3 outstanding scientists. Dr. Thomas Shenk, virologist, Dr. Darell D. Bigner, glioma expert and Dr. Robert Martuza, a leader in viral oncolysis and clinical studies. All efforts will be focused on the flmely translation of the flndings on molecular biology of herpes simplex viruses and the cellular biology of the virus-host relation to the treatment of human malignant gliomas. This program project grant has the full support of the University of Alabama at Birmingham and the University of Chicago. Letters of support appear from Drs. C Garrison (President, UAB), E Capiluto (Provost, UAB), R Rich (Dean, School of Medicine, UAB), E Partridge (Director, UAB Comprehensvive Cancer Center), S Stagno (Chair, Department of Pediatircs) and M. LeBeau (Director, The University of Chicago Cancer Center).

Public Health Relevance

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA071933-14
Application #
8378341
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$95,934
Indirect Cost
$37,954
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Jackson, Joshua D; Markert, James M; Li, Li et al. (2016) STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res 14:482-92
McFarland, Braden C; Marks, Margaret P; Rowse, Amber L et al. (2016) Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma. Oncotarget 7:20621-35
Friedman, Gregory K; Moore, Blake P; Nan, Li et al. (2016) Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18:227-35
Friedman, Gregory K; Beierle, Elizabeth A; Gillespie, George Yancey et al. (2015) Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2:
Shu, Minfeng; Du, Te; Zhou, Grace et al. (2015) Role of activating transcription factor 3 in the synthesis of latency-associated transcript and maintenance of herpes simplex virus 1 in latent state in ganglia. Proc Natl Acad Sci U S A 112:E5420-6
Dobbins, G Clement; Ugai, Hideyo; Curiel, David T et al. (2015) A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents. PLoS One 10:e0145272
Cripe, Timothy P; Chen, Chun-Yu; Denton, Nicholas L et al. (2015) Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2:
Friedman, G K; Nan, L; Haas, M C et al. (2015) γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22:348-55
Jackson, J D; McMorris, A M; Roth, J C et al. (2014) Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 21:984-90
Roth, Justin C; Cassady, Kevin A; Cody, James J et al. (2014) Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25:16-27

Showing the most recent 10 out of 163 publications